GE Healthcare, InSightec sign worldwide sales and marketing agreement for ExAblate 2000

GE Healthcare, announced a new worldwide distribution/sales representation agreement with InSightec Image Guided Treatment Ltd. for the sales and marketing of ExAblate 2000, the first MRI-guided, focused ultrasound system designed to non-invasively treat uterine fibroids.

Under the terms of the agreement, GE, a minority shareholder in InSightec, will have exclusive worldwide distribution rights for ExAblate 2000 with the exception of Japan and Russia where InSightec has existing distributors and representatives. InSightec and GE also will collaborate on research and development and marketing. The agreement is for five years, effective immediately.
    
ExAblate 2000 is a non-invasive therapy system that combines MRI with highly focused ultrasound to thermally ablate tumors in the body. It is only compatible with GE's MR systems. ExAblate 2000, in combination with GE's Signa MR system, allows physicians to locate and measure the size of a tumor before precisely ablating it through concentrated sound wave energy without incision. It also gives doctors real-time therapy planning capabilities through tools that monitor thermal effects, ensuring the procedure's efficacy and the patient's safety.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup